Sangamo Therapeutics, Inc.

NASDAQ:SGMO

Biotechnology

Healthcare
$0.18 +2.06%

+$0.00 today

Market cap
$70.43M
Beta
1.29
P/E (TTM)
-0.5
EPS (TTM)
-$0.32
52W Low $0.10High $0.77

Volume 0.61M

Average 9.53M

SGMO Common Stock Issued

Cash raised by issuing new shares.

Sangamo Therapeutics, Inc.NASDAQ: SGMO

Common Stock Issued · Q1 FY2026 · quarter ended Mar 2026

Common stock issued grows, but more slowly than its trailing trend

Q1 FY2026 common stock issued of $27.08M rose 161.3% year over year, behind the +439.2% change in trailing-twelve-month common stock issued. Sequentially, it rose 78.8% from the prior quarter. Over 3 fiscal years it compounded at -4.5% a year.

Context

  • Common stock issued amounted to 187.1% of revenue in FY2025, up 137.0 pp from a year earlier.
  • Common stock issued increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from +161.3% toward the trailing-twelve-month pace of +439.2%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$27.08M+78.8% QoQ
Last fiscal yearDec 2025
$74.01M+155.3% YoY
LTMMar 2026
$90.73M+439.2% YoY
Common Stock Issued past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+161.3%——
1 year+155.3%——
3-year CAGR-4.5%——
5-year CAGR——
10-year CAGR——

Common Stock Issued history

USD · from the cash flow

Latest · FY2025
74.01M USD
Year-over-year change
+155.3%
4-year CAGR
+28.6%

Common Stock Issued vs competitors

How SGMO compares with its peers on the latest reported figures

  • Peers report in different currencies, so common stock issued is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +439.2% is the 6th highest of 11, against a peer median of +635.9%.
  • Common stock issued amounts to 262.5% of revenue for SGMO, versus a peer median of 386.2%.
SGMO Competitors
Common Stock Issued for SGMO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IVVDInvivyd, Inc.LTM Mar 2026$215.74M USD+71102.0%+650.6%386.2%
CCCCC4 Therapeutics, Inc.LTM Mar 2026$126.82M USD+1104.7%+445.8%363.8%
MISTMilestone Pharmaceuticals Inc.LTM Mar 2026$104.89M USD+75017.8%+219.2%5879.2%
SGMOSangamo Therapeutics, Inc.LTM Mar 2026$90.73M USD+439.2%-4.5%262.5%
RANIRani Therapeutics Holdings, Inc.LTM Mar 2026$58.23M USD+213.9%+477.6%1837.6%
OABIOmniAb, Inc.LTM Mar 2026$28.32M USD+880.3%-33.5%98.0%
IMDXInsight Molecular Diagnostics Inc.LTM Mar 2026$24.84M USD-56.4%-4.4%1274.6%
CDXSCodexis, Inc.LTM Mar 2026$16.94M USD-47.7%+170.3%21.7%
IPHAInnate Pharma S.A.FY2025€14.39M EUR+391.5%+317.3%516.3%
ARMPArmata Pharmaceuticals, Inc.LTM Mar 2026$1.36M USD+1447.7%-75.5%46.0%
MOLNMolecular Partners AGLTM Mar 2026CHF 73.01K CHF+82.5%-36.8%—
Peer median (excluding SGMO) —+635.9%+194.8%386.2%

Competitors are the stored peer set for SGMO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(178.3M)(192.28M)(257.83M)(97.94M)(122.93M)
Depreciation & Amortization17.64M20.56M22.19M9.36M7.6M
Deferred Income Tax2.77M0(6.34M)00
Stock-Based Compensation32.96M31.65M27.36M12.38M9.08M
Change in Working Capital(101.9M)(82.32M)(164.03M)4.51M(4.22M)
Accounts Receivables(789K)2.34M(976K)953K155K
Inventory7.66M0000
Accounts Payables(7.66M)13.35M5.59M(14.17M)2.79M
Other Working Capital(101.11M)(98M)(168.65M)17.72M(7.17M)
Other Non-Cash Items(6.43M)(1.24M)153.8M4.55M13.27M
Operating Cash Flow(233.25M)(223.63M)(224.84M)(67.14M)(97.21M)
Capital Expenditures(23.28M)(20.17M)(21.16M)(267K)(102K)
Acquisitions (Net)(119K)(79.46M)01.95M0
Purchases of Investments(338.16M)(277.39M)(59.55M)00
Sales of Investments609.76M356.85M234.24M35.84M0
Other Investing Activities079.46M000
Investing Cash Flow248.2M59.29M153.53M37.52M(102K)
Debt Repayment00000
Common Stock Issued27.1M84.87M15.11M28.99M74.01M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities5.76M(209K)(518K)(614K)(3.26M)
Financing Cash Flow32.86M84.66M14.59M28.38M70.75M
Effect of Forex Changes(263K)1.25M1.48M(2.05M)4.09M
Net Change in Cash47.54M(78.43M)(55.24M)(3.29M)(22.47M)
Free Cash Flow(256.53M)(243.8M)(246M)(67.41M)(97.31M)

Sangamo Therapeutics, Inc.

NASDAQ:SGMO

Intrinsic Alpha fair value

Locked

Current Price

$0.18

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.